Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P06889 (
Mol
)
630,302
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The pattern of transcriptional activation by 17beta-estradiol (E2) and 4-hydroxytamoxifen (4-OHT) was determined in ZR-75 and MDA-MB-231 breast, ECC1 and HEC1A endometrial and HepG2 liver cancer cell lines cotransfected with E2-responsive constructs and wild-type estrogen receptor alpha (ER alpha) or
ER beta
(
ER beta
) or variant forms of ER alpha expressing activation function 1, AF1 (ER alpha-AF1) or activation function 2, AF2 (ER alpha-AF2). The E2-responsive constructs contained promoter inserts from the human complement C3 (pC3), human cathepsin D (pCD) and rat creatine kinase B (pCKB) genes. Minimal
ER beta
-dependent transactivation (<2.5-fold induction) was observed for E2 only in ECC1 and MDA-MB-231 cells transfected with pCKB or pC3, whereas 4-OHT was inactive as an
ER beta
agonist for all promoters in the four cell lines. The ER alpha agonist and/or antagonist activities for E2 and 4-OHT were highly variable and the transactivation was dependent on ER subtype, ER alpha variant expressed, gene promoter, and cell context. For example, E2 did not activate pCD in HepG2 cells transfected with wild-type or variant ER alpha, whereas E2 activated reporter gene activity in the four endometrial and breast cancer cell lines transfected with ER alpha and pCD, pCKB or pC3. Hormone activation of these constructs by ER alpha-AF1 or ER alpha-AF2 was highly variable among the different cell lines and even in the same cell line transfected with the three E2-responsive constructs. Similar variability was observed for 4-OHT. For example, 4-OHT activates pC3 in HepG2 cells transfected with ER alpha or ER alpha-AF1, and pCKB in HEC1A cells. However, AF1-dependent activation by 4-OHT is not observed for pCKB in ECC1 cells or for pC3 and pCD in HEC1A or ECC1 endometrial cancer cells. The results of this study suggest that transcriptional activation by E2 and 4-OHT induces recruitment of different transcription factor complexes that are dependent on the cell type and also the gene promoter.
J Steroid Biochem
Mol
Biol 2003 Jan
PMID:17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context. 1264 21
In our recent reports, the novel isoform cDNAs of the ER alpha (ER alpha isoform S cDNA),
ER beta
(
ER beta
isoform M cDNA) and PR (PR isoform S and PR isoform T cDNAs) have been identified. These isoform cDNAs contained the previously unidentified 5'-sequences on exons 4-8 (ER alpha isoform S cDNA), exons 5-8 (
ER beta
isoform M cDNA) or exons 4-8 (PR isoform S and PR isoform T cDNAs). The genomic DNA analysis revealed that the 5'-sequences were derived from the novel independent exons, the ER alpha exon S,
ER beta
exon M, PR exon S and PR exon T, respectively. Furthermore, the existence of the novel variant mRNA, termed the i45 PR mRNA variant, with the insertion of the previously unidentified exons, termed the exons i45a and i45b, has been demonstrated by the reverse transcription-polymerase chain reaction on the RNA of the human uterine endometrium. From these results, we have concluded that the genes for the human female sex steroid hormone receptors contain the novel intronic exons, that the novel isoform mRNAs are transcribed using the intronic exon and exons 4-8 (or exons 5-8) of the gene, and that the novel variant mRNA is generated by the insertion of the intronic exons in the PR. In the present communication, our recent data along with others on the novel isoform/variant mRNAs for the human female sex steroid hormone receptors will be summarized.
J Steroid Biochem
Mol
Biol 2002 Dec
PMID:Novel isoforms of the mRNA for human female sex steroid hormone receptors. 1265 Jun 98
Various
estrogen receptor beta
exon-deleted variant (
ER-beta
EDV) mRNAs were expressed in human ovary and uterine endometrium.
Estrogen receptor beta
(
ER-beta
) completely or partially deleted exon n is expressed as
ER-beta
EnDV or En'DV, respectively. The mRNAs for
ER-beta
single exon-deleted variant (EDV),
ER-beta
E2DV, E4DV, E5DV and E6DV; for
ER-beta
double exon-deleted variants,
ER-beta
E1'+2DV, E4+5DV and E5+6DV; and for
ER-beta
triple exon-deleted variants,
ER-beta
E2'+3+4DV and E4+5+6DV were detected. In
ER-beta
E2DV, E4+5DV, E5DV and E6DV mRNAs, the new stop codon is made in the exon following the deleted exon(s), and the new proteins may lack the corresponding domains. In
ER-beta
E1'+2DV, E2'+3+4DV, E4DV, E4+5+6DV and E5+6DV mRNAs, the original stop codon is still present, and the new proteins may conserve the new short amino acid sequences surrounding the deleted exons.
ER-beta
E1'+2DV, E2DV, E2'+3+4DV, E4DV, E4+5DV and E4+5+6 are unlikely to work as a transcription factors. On the other hand,
ER-beta
E5DV, E6DV and E5+6DV lack only the ligand-binding domain, and might work as dominant positive or negative factors. Therefore,
ER-beta
E5DV, E6DV and E5+6DV, constitutively expressed in human ovary and uterine endometrium might, in part regulate estrogen responsiveness.
J Steroid Biochem
Mol
Biol 2003 Feb
PMID:Expression of estrogen receptor beta exon-deleted variant mRNAs in ovary and uterine endometrium. 1271 Sep 96
Extracts from red clover (Trifolium pratense), soybean (Glycine max.) and black cohosh (Cimicifuga racemosa) are frequently used as alternative compounds for hormone replacement therapy (HRT) to treat menopausal disorders. Fifteen commercially available products made either from red clover, soybean or black cohosh were tested in in vitro assays in this study. The main polycyclic phenolic compounds of soy and red clover products were biochanin A, genistein, daidzein, formononetin, and glycitein. In red clover products glycitein was not abundant. All the compounds showed clear estrogenic activity through estrogen receptor alpha (ERalpha) and
estrogen receptor beta
(ERbeta) and affinity to progesterone receptor (PR) and androgen receptor (AR), whereas the compounds from black cohosh did not. This was corroborated by synthetic isoflavones such as biochanin A, daidzein, genistein and formononetin. They exerted affinity to PR and AR in the range of 0.39-110 mM. Statistical analysis applying principal component analysis (PCA) revealed that all red clover and soy products are grouped in different clusters. Red clover products showed a higher affinity to AR and PR than soy products, which is explained by the higher amount of isoflavones present. In vitro assays and chemical analysis showed that theoretical estrogenic activity expressed as equivalent E2 concentration is in the same range as recommended for synthetic estrogens. Broader spectrum of action and hypothesized lower side effects by action through ERbeta make them suitable for alternative hormone replacement therapy.
J Steroid Biochem
Mol
Biol 2003 Feb
PMID:Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. 1271 Oct 12
Estrogen is the natural agonist of the estrogen receptor (ER). However, certain plant-derived compounds or phytoestrogens have been identified that mimic estrogens and act as agonists and/or antagonists of ERs, depending on subtype and target tissue. Using thin layer chromatography (TLC), gas chromatography-mass spectrometry (GC-MS), and proton nuclear magnetic resonance (1H-NMR), we identified a simple phenol, 4-ethoxymethylphenol (4EM), found in Maclura pomifera that acts as an agonist of ER-alpha and
ER-beta
in HeLa and MCF-7 cells. To study the effect of 4EM on ER-alpha and
ER-beta
activity, we performed transient transfection assays and showed that 4EM activated ER-dependent gene transcription in a dose-dependent manner on both ER subtypes and this activity was inhibited by trans-4-hydroxytamoxifen (4HT). Further, 4EM-mediated transcription in ER-alpha, like estrogen, was enhanced in the presence of coactivators, steroid receptor coactivator-1 (SRC-1), CREB binding proteins (CBP), and E6-associated protein (E6-AP). We found that 4EM was specific for ER and did not activate transcription of the progesterone receptor.
J Steroid Biochem
Mol
Biol 2003 Mar
PMID:4-ethoxymethylphenol: a novel phytoestrogen that acts as an agonist for human estrogen receptors. 1273 88
In the last decades, substances with estrogenic activity have been dispersed into the environment. Xenoestrogens act by binding to estrogen receptors, ligand-regulated transcription factors, for which two subtypes have been described, ER-alpha and
ER-beta
, which are often coexpressed at variable amounts in different tissues. We investigated variations in the expression of ER-alpha and
ER-beta
mRNAs following treatment with four xenoestrogens (bisphenol A, 4-tert octylphenol, 2-hydroxybiphenyl, 4-hydroxybiphenyl) and with 17beta-estradiol in estrogen-sensitive (T47D) and estrogen-insensitive (BT20) breast cancer cell lines. Although to a variable extent, both estradiol and the tested xenoestrogens increased the expression of
ER-beta
mRNA, whereas a slight effect on ER-alpha was observed only in T47D cells. Upregulation of
ER-beta
expression by estradiol and xenoestrogens was observed only in the presence of detectable ER-alpha protein levels. These findings indicate a regulatory role for
ER-beta
in ER-alpha-mediated transcription and a role for
ER-beta
in mediating xenoestrogen toxicity.
Cell
Mol
Life Sci 2003 Mar
PMID:Selective modulation of ER-beta by estradiol and xenoestrogens in human breast cancer cell lines. 1273 16
In this work, we determined the expression pattern and the hormonal regulation of progesterone receptor (PR) isoforms in the rat lung of ovariectomized female rats after estradiol (E2) and progesterone (P4) treatments. We also evaluated the content of
estrogen receptor beta
(
ER-beta
) which is the ER isoform expressed in the lung. RNA and proteins were extracted and processed for reverse transcription (RT) coupled to polymerase chain reaction (PCR) and Western blot, respectively. The expression of both PR isoforms in the lung at mRNA and at protein levels was up-regulated by E2 while P4 down-regulated it at mRNA level. P4 did not modify PR isoforms protein content unlike its effect in the uterus where both PR isoforms were down-regulated by their ligand at mRNA and protein levels. PR-A was the predominant isoform, both in the lung and in the uterus. In the lung,
ER-beta
was down-regulated by E2 while P4 did not significantly modify the effect of E2. These results suggest that both PR isoforms should be expressed in the rat lung, and that their expression should be differentially regulated at mRNA and at protein levels by P4. We also suggest that the up-regulation of PR isoforms by E2 in the lung is mediated by
ER-beta
.
J Steroid Biochem
Mol
Biol 2003 May
PMID:Regulation of progesterone receptor isoforms expression by sex steroids in the rat lung. 1279 54
Numerous epidemiological studies have pointed out a higher frequency of temporomandibular disorder (TMD) in women than in men, which indicates the involvement of a sex hormone, such as estrogen, in the pathogenesis of TMD. Although estrogen is known to play pivotal roles in osteoarthrosis or rheumatoid arthritis in systemic joints, there have been few reports about the role of estrogen in the temporomandibular joint (TMJ). The effect of estrogen is generally mediated by the estrogen receptors (ERs) ER alpha (the predominant type) and
ER beta
. In this study we examined the expression of ER alpha protein and mRNA in the TMJ of adult male rats by immunocytochemistry and in situ hybridization histochemistry. Intense ER alpha immunoreactivity was localized in the synovial lining cells, stromal cells in the articular disc, and chondrocytes in the TMJ. These ER alpha-immunopositive synovial lining cells are characteristic of cytoplasmic processes identified with confocal and immunoelectron microscopy, which indicates that they are synovial type B cells. In situ hybridization histochemistry confirmed intense signals for ER alpha in the synovial lining cells and the sublining fibroblasts at mRNA levels. The nuclei of chondrocytes showed an intense immunoreaction for ER alpha in the maturative and hypertrophic layers of the articular cartilage. In addition to the nuclear localization of ER alpha, a weak immunoreaction appeared in the cytoplasm of some ER alpha-positive cells. These findings support the hypothesis that TMJ tissue-at least in the male rat-has the potential to be an estrogen target tissue.
Anat Rec A Discov
Mol
Cell Evol Biol 2003 Oct
PMID:Expression of estrogen receptor alpha (ER alpha) in the rat temporomandibular joint. 1297 17
The dose-dependent effect of a 24 h treatment with estradiol (E(2)) (1, 2, 5, 10 nM) and raloxifene (Rx) (1, 5, 10, 20 microM) on ER alpha and
ER beta
mRNA expression, collagen bio-synthesis, prolidase activity, MMP-2, MMP-9, insulin-like growth factor I receptor expression (IGF-1R) and beta1-integrin expressions in cultured fibroblasts obtained from postmenopausal women were examined. Both ligands increased mRNA expression of ER compared to control. Rx at 5 and 10 microM concentrations had greater stimulative effect on collagen biosynthesis, prolidase activity and IGF-1R expression compared to E(2) at 2 and 5 nM concentration. Both studied ER ligands had no effect on beta1-integrin receptor expressions. MMP-2 expression was not detected in human skin fibroblast culture. In contrast to estradiol raloxifene inhibited the expression of MMP-9. Raloxifene had stronger positive stimulative effects on collagen biosynthesis, through different biochemical mechanisms, than estradiol in human skin fibroblasts and might reverse some of the postmenopausal changes in skin or connective tissue. Increase of collagen synthesis induced by raloxifene may be activated by both estrogen receptor dependent and independent pathways such as up-regulation of estrogen receptors, up-regulation of IGF receptor, transcriptional regulation of collagen genes by estrogen receptor-raloxifene complex, increasing of prolidase activity or finally by inhibition of MMP-9 expression.
Int J
Mol
Med 2003 Nov
PMID:Differential effects of estradiol and raloxifene on collagen biosynthesis in cultured human skin fibroblasts. 1453 13
Both estrogen and selective estrogen receptor modulators (SERMs) such as tamoxifen and raloxifene have been demonstrated to lower plasma low density lipoprotein (LDL)-cholesterol concentrations by stimulation of LDL receptor gene expression. To determine the molecular mechanisms of estradiol- and tamoxifen-induced LDL receptor expression, we performed transient transfection experiments with luciferase reporter gene-constructs under transcriptional control of the human LDL receptor promoter. We demonstrate, that estradiol and tamoxifen stimulate LDL receptor gene expression in human HepG2 hepatoma cells only when estrogen receptor (ER)-alpha but not when
ER-beta
is cotransfected. Deletion mutants and point mutations of the LDL receptor promoter reveal that estradiol- and tamoxifen-stimulated expression of this gene depends on an intact repeat 3 in the LDL receptor promoter, a cis-element previously shown to interact with Sp1. Gel mobility analyses demonstrated estradiol- and tamoxifen-stimulated binding of nuclear proteins to repeat 3 (bp -56 to bp -36) of the LDL receptor promoter. These data provide an alternative mechanism of LDL receptor gene expression by non-classical estradiol- and tamoxifen-stimulated induction through an ER-alpha/Sp1 complex.
J Steroid Biochem
Mol
Biol 2003 Aug
PMID:Estrogen receptor-alpha and Sp1 interact in the induction of the low density lipoprotein-receptor. 1456 62
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>